Cegedim H1 2026 slides: Q2 growth accelerates as e-invoicing lifts outlook

Cegedim reported H1 2026 revenue of €324.8M (+0.7% reported, +0.8% like-for-like) with a clear Q2 inflection: Q2 revenue rose 2.5% (+2.4% like-for-like) after a 1.0% decline in Q1. Growth was led by Business Services (+5.5% in Q2; €95.7M in H1, +4.2% reported) while Cloud & Support dragged performance (-16.4% reported in H1). Management reiterated a full-year 2026 outlook for like-for-like revenue growth above 2% and expects e-invoicing setup to transition to volume-based billing in early 2027; shares were up 1.78% at ~$10.30.

Analysis

The near-term winner is the company’s compliance/transaction layer, not the legacy software franchises. Regulatory deadlines create forced purchasing before there is visible ROI, which supports a revenue air-pocket into the September implementation window and then a likely digestion phase once clients have onboarded. The second-order beneficiary is anyone with implementation capacity and switching costs; the losers are smaller e-invoicing vendors that can win pilots but not survive a post-launch consolidation wave.

The market should focus more on cash conversion than reported growth. Management is effectively trading current margin and FCF for a 2027 monetization step-up, so the setup looks better on EBIT than on valuation if the stock rerates too early. The main falsifier is a Q3/Q4 deceleration in Business Services or evidence that e-invoicing demand was mostly pull-forward rather than net new recurring volume; because the business is heavily France-centric, any administrative delay or rollout friction would hit the thesis fast.

Contrarianly, the consensus may be too pessimistic on the durability of the setup spend and too optimistic on immediate upside from the reform. The underappreciated issue is that the healthcare software segments still face share pressure from better-capitalized incumbents, so the stock likely needs proof of margin expansion, not just top-line acceleration, to sustain a rerating. In other words, this is a months-to-years story, but the first 1-3 month trade is mostly about whether the pre-launch surge keeps compounding into the next print.

Key Decisions for Investors

• Starter long CGM (Cegedim) on any 3-5% post-results pullback; 3-6 month horizon, with upside if Business Services growth stays >4% and downside if the pre-buy narrative fades.
• Treat this as a cash-flow-sensitive name: if free cash flow guidance deteriorates further into Q3, cut the position even if revenue holds up, because the market will likely punish the setup phase harder than EBIT.
• For a relative-value expression, pair long CGM vs short a broad small-cap European software/IT basket if you need to own the e-invoicing/regulatory workflow thesis without paying full multiple for generic software beta.
• Set a hard watch item for the first post-September read-through: if order flow or revenue growth does not re-accelerate after the reform date, take profits on the long and assume the move was mostly pull-forward.
• No direct trade in GOOGL or TSLA from this note; the signal here is idiosyncratic and small-cap, and forcing exposure through high-beta mega-caps would be the wrong expression.